| Literature DB >> 30507195 |
Lena Trifonov, Vadim Nudelman1, Michael Zhenin, Erez Matsree1, Michal Afri, Bruria Schmerling, Guy Cohen2, Krzysztof Jozwiak3, Michal Weitman, Edward Korshin, Hanoch Senderowitz, Asher Shainberg, Edith Hochhauser1, Arie Gruzman.
Abstract
TLR4, a member of the Toll-like receptor (TLR) family, serves as a pattern recognition receptor in the innate immune response to microbial pathogens. TLR4 also regulates the inflammatory reaction to ischemic injury in the heart. The TRIF-related adaptor molecule (TRAM) is an adapter that recruits the Toll/interleukin 1 receptor (TIR) domain, which contains adapter-inducing IFN-β (TRIF), to activate TLR4, following TRIF-dependent cytokine gene transcription. On the basis of a known TRAM-derived decoy peptide, 10 of its peptidomimetics were synthesized. One of them, 1-benzyl-5-methyl-4-( n-octylamino)pyrimidin-2(1 H)-one (21), exhibited high potency and efficacy in vitro. In vitro results and in silico analysis provided evidence for the possible direct interaction of 21 with the TLR4 complex. Administered in mice, 21 was able to block the pathophysiological manifestation of MI, restoring the concomitant tissue damage, with a 100% survival rate. Thus, inhibition of TLR4-mediated inflammation in postischemic myocardium could be used as an approach for developing cardioprotective drugs.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30507195 DOI: 10.1021/acs.jmedchem.8b01471
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446